Related Experiment Video
Updated: Jan 15, 2026
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
Published on: September 20, 2018
Management of childhood granulomatous periorificial dermatitis with clarithromycin: A retrospective cohort study
Yizhu Xiao1, Jingyi He1, Anwei Chen1
1Department of Dermatology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China.
Insights
Oral clarithromycin effectively treats childhood granulomatous periorificial dermatitis, with 95.4% clearing. This systemic therapy is safe and beneficial for moderate-to-severe pediatric cases, reducing scarring risks.
Area of Science:
- Pediatric Dermatology
- Dermatological Therapeutics
- Clinical Research
Background:
- Childhood granulomatous periorificial dermatitis is increasing, with suboptimal topical treatments.
- Severe cases risk chronicity and scarring, necessitating systemic alternatives.
- Oral clarithromycin shows potential, but pediatric data is limited.
Purpose of the Study:
- Evaluate oral clarithromycin's efficacy and safety in pediatric granulomatous periorificial dermatitis.
- Assess treatment outcomes, including clearance, recurrence, and scarring.
- Determine clarithromycin's role in managing moderate-to-severe pediatric cases.
Main Methods:
- Retrospective analysis of 43 pediatric patients treated with oral clarithromycin.
- Outcomes assessed included treatment efficacy, adverse events, and scar incidence.
- Correlation analysis between treatment duration, disease severity, and duration.
Main Results:
- 95.4% of patients achieved clearance after a median of 10 weeks of clarithromycin.
- Scarring occurred in 14.6% of cases, primarily in moderate-to-severe presentations.
- No severe adverse events were reported; treatment duration correlated with severity.
Conclusions:
- Oral clarithromycin is an effective and well-tolerated systemic therapy for pediatric granulomatous periorificial dermatitis.
- Timely systemic intervention is crucial for moderate-to-severe cases to minimize scarring.
- Clarithromycin offers a valuable option for refractory pediatric cases.
Background:
Childhood granulomatous periorificial dermatitis incidence is increasing, yet topical therapies remain suboptimal with chronicity and scarring risks in severe cases. Systemic alternatives are urgently needed. Although oral clarithromycin shows promise, its efficacy/safety evidence in pediatric populations lacks robustness.
Objective:
This study evaluated the effect of clarithromycin on a pediatric group with granulomatous periorificial dermatitis.
Methods:
This retrospective study analyzed 43 patients treated with oral clarithromycin, with outcomes including treatment efficacy, adverse event incidence, and scar incidence.
Results:
All patients completed clarithromycin therapy (median 10 weeks; 2-26). At 6 months, 95.4% (41/43) cleared, with 2.3% each recurrence and nonresponse. Treatment duration correlated with both baseline severity (r = 0.592, P < .01) and disease duration (r = 0.590, P < .01). Scarring (14.6%) occurred only in moderate-to-severe cases, which showed greater severity (P = .039) and longer courses (P = .028). No severe adverse events occurred.
Limitations:
This is a retrospective study without case controls and is subject to interviewer and memory bias.
Conclusion:
For moderate-to-severe or stubborn cases, timely evaluation and tailored systemic interventions are critical to mitigate scarring risks. Clarithromycin is an effective and tolerated therapy in children with moderate-to-severe and refractory granulomatous periorificial dermatitis.
